Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Construction in Progress (2018 - 2021)

Ascendis Pharma A (ASND) has disclosed Construction in Progress for 4 consecutive years, with $2173.5 as the latest value for Q4 2021.

  • Quarterly Construction in Progress fell 20.74% to $2173.5 in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $2173.5 through Dec 2021, down 20.74% year-over-year, with the annual reading at $2173.5 for FY2021, 20.74% down from the prior year.
  • Construction in Progress hit $2173.5 in Q4 2021 for Ascendis Pharma A, down from $2742.3 in the prior quarter.
  • In the past five years, Construction in Progress ranged from a high of $3.0 million in Q4 2019 to a low of $2173.5 in Q4 2021.
  • Historically, Construction in Progress has averaged $805448.0 across 4 years, with a median of $115510.8 in 2018.
  • Biggest five-year swings in Construction in Progress: surged 1209.18% in 2019 and later plummeted 99.91% in 2020.
  • Year by year, Construction in Progress stood at $228279.3 in 2018, then surged by 1209.18% to $3.0 million in 2019, then tumbled by 99.91% to $2742.3 in 2020, then fell by 20.74% to $2173.5 in 2021.
  • Business Quant data shows Construction in Progress for ASND at $2173.5 in Q4 2021, $2742.3 in Q4 2020, and $3.0 million in Q4 2019.